Could a common heart drug prevent deadly bleeding in liver disease?
NCT ID NCT06861075
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This study tests whether carvedilol, a beta-blocker, can reduce high blood pressure in the liver's portal vein in people with cirrhosis. High pressure can lead to life-threatening bleeding. Thirty adults with cirrhosis and signs of portal hypertension will take carvedilol for one month. The main goal is to see if liver pressure drops by at least 10% using a special ultrasound probe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Estaing Medecine Digestive Et Hepatobiliaire
RECRUITINGClermont-Ferrand, 63003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lise Laclautre
NOT_YET_RECRUITINGClermont-Ferrand, 63000, France
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carvedilol (a beta-blocker drug)
What this could lead to
If it works, this could offer a simple way to prevent dangerous internal bleeding in people with cirrhosis.
What could go wrong
This is a very small, early-phase study with only 30 people. The drug may not lower liver pressure enough, and beta-blockers can cause side effects like dizziness or fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.